CME

Faculty: Carolyn Lam, MD, PhD Faculty: Stephen J. Greene, MD Using a real-world patient case, Dr. Stephen Greene and Dr. Carolyn Lam explore strategies to optimize care for patients with heart failure with reduced ejection fraction (HFrEF) who remain at elevated risk despite guideline-directed medical therapy (GDMT). The discussion examines the importance of avoiding clinical inertia, addressing...

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom...

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom...

Faculty: Michael A. Levine, MD, ML, MACE Faculty: Aliya Khan, MD, FRCPC, FACP, FACE, FASBMR In this expert discussion, Drs. Michael Levine and Aliya Khan review emerging evidence in autosomal dominant hypocalcemia type 1 (ADH1), including findings from the CALIBRATE trial presented at ENDO 2026. They discuss how CaSR-targeted therapy with encaleret may address the underlying disease mechanism and...

Faculty: Neal Ready, MD, PhD This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell...

Faculty: Ticiana Leal, MD This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell...

Faculty: Ticiana Leal, MD This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell...

Faculty: Sara A. Hurvitz, MD, FACP Faculty: Tiffany Traina, MD, FASCO The role of antibody-drug conjugate (ADC) therapy has been well established in metastatic breast cancer. Recent phase 3 data have provided evidence for expanded indications for early breast cancer and triple-negative breast cancer (TNBC), leading to updates in current treatment guidelines. In this case-based activity, Drs....

Faculty: Neal Ready, MD, PhD This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell...